IXICO PLC (LSE:IXI, OTC:PHYOF) CEO Bram Goorden talked with Proactive about the company’s innovation-led growth strategy, spotlighting advancements in its AI-driven neuroimaging platform. Goorden explained that upcoming vascular biomarkers for Alzheimer’s are expected in Q3, followed by a novel neuromelanin biomarker for Parkinson’s in Q4. These innovations are aimed at further differentiating IXICO in the competitive landscape of CNS-focused clinical research.
Goorden said, “We’re the only imaging analytics company that is so focused on CNS, so on the central nervous system or on the brain,” positioning IXICO as a distinct player in neurodegenerative research. He emphasised the company’s strategy to build its commercial and operational footprint, especially by expanding presence in the US and deepening partnerships with pharma and biotech firms.
In addition to its established presence in Huntington’s disease, IXICO is pushing deeper into Alzheimer’s and Parkinson’s, while also expanding revenue stream opportunities in post-marketing surveillance and clinical decision support. The platform, which has undergone significant investment, is now equipped for broader applications and potential collaborations with CROs and big data firms.
The company’s £13 million+ order book underpins full revenue visibility for 2025 and 75% visibility for 2026. IXICO also expects continued traction in Alzheimer's-related projects as more therapies reach the market.
For more interviews like this, visit Proactive’s YouTube channel. Don’t forget to like the video, subscribe, and hit the notification bell for future updates.
#IXICO #AlzheimersResearch #ParkinsonsResearch #Biomarkers #AIinHealthcare #Neuroimaging #ClinicalTrials #CNSdisorders #HealthcareAI #ProactiveInvestors
